iLite® ADCC Activity Assay 
Product Line

The iLite ADCC Activity Assay product line, is a reporter gene system which is unique in its set-up. The product line includes ADCC Effector Assay Ready Cells and various Target Assay Ready Cells, engineered to work optimally together and give unparalleled sensitivity. 

Each iLite ADCC Activity Assay includes Effector and Target cells as well as a negative control cell line for each specific target. The control cell line allows screening for unspecific activation of ADCC, giving added value to each experiment.

As the majority of the iLite cell lines, the iLite ADCC Effector (V) Assay Ready Cells also have a secondary luciferase readout, from a luciferase expressed under the control of a constitutive promotor. This enables normalization of each individual readout according to cell number and thereby accounts for any potential matrix effects.

Click the picture to see a bigger picture

Figure 1. The interaction between the reporter gene effector cell and the target cell, generated by the crosslinking of the two cells via a specific drug antibody. The resulting luminescence originates exclusively from this crosslinking and the signaling from the CD16 receptor to the Firefly Luciferase promoter. The strength of the luminescence correlates to the drugs ability to induce ADCC.

All components of the ADCC Activity Assays are available individually, and the Effector cells can be used with any iLite Target cell, or a target cell line of your choice.

ADCC Activity Assays in the Drug Development Process

The activity of many antibody-based therapeutics is mediated in part by their ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and thereby enhancing the body's own immune response towards dysfunctional cells. By analyzing the ADCC activity induced by different drugs or drug candidates, a measure of both drug potency and unwanted side effects can be provided.

As such, the iLite ADCC Activity Assay product line is a valuable tool for the whole drug development process, measuring the ability of a drug to induce ADCC activity in a straight forward, sensitive and reproducible manner. 

Click the picture to see a bigger picture

Figure 2. When the target cell has been depleted for the specific surface target molecule, the crosslinking between the effector and the target cell cannot be established and hence no luminescence from Firefly Luciferase is generated. However, luminescence from the normalization gene NanoLuc, which is expressed under a constitutive promotor, is still present. 

    Key benefits of iLite® ADCC Activity Assays:

          - Unparalleled sensitivity - LLOQ 1pg/mL
          - High serum tolerance - no ADCC activation by serum
          - Normalization read-out included
          - Negative control available for screening of unspecific activity
          - Easy to use – no culturing required of target or effector cells

NOW LAUNCHING - iLite anti-CD20 ADCC Activity Assay

The launch of iLite Assay Ready Cells for use in anti-CD20 antibody development and manufacturing brings the first four products from Euro Diagnostica's ADCC product line to market and showcases the unique set-up of the iLite technology:

The first, iLite® ADCC Effector (V) Assay Ready Cells, are human cells which express high levels of FcyRIIIa (CD16) and a Firefly Luciferase (FL) reporter gene. The cells, engineered to have a high tolerance for serum, also include a second reporter gene which allows for normalization of cell counts, serum matrix effects or lysis of the effector cells by the target cells.

The second product, iLite® ADCC Target CD20 (+) Assay Ready Cells, are human cells engineered to overexpress CD20 and are optimized to give high sensitivity and specificity when used together with iLite® ADCC Effector (V) Assay Ready Cells.

Since unspecific activation of ADCC can be a confounding factor when performing ADCC assays, the iLite® ADCC Target CD20 (-) Assay Ready Cells, which are depleted of CD20 expression, are also provided to be used as a control.

All three products are combined in the iLite® anti-CD20 ADCC Activity Set. This set of cells enables measurements of an anti-CD20 drug’s ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC) in a straightforward, sensitive and reproducible manner. 

Interested in trying iLite® ADCC Activity Assays?

Click here to contact us today!

For more information on the first
iLite anti-CD20 ADCC Activity Set



COMING SOON - iLite® ADCC Activity Assay Product Line


Euro Diagnostica will continuously expand the iLite® ADCC Activity Assay product line with novel and higly specific target cells.


Follow us on LinkedIn to stay up to date with
news and upcoming launches - including
ADCC HER2 and EGFR target cells

In accepting delivery of iLite® Assay Ready Cells the recipient agrees not to sub-culture these cells, attempt to sub-culture them or to give them to a third party recipient, and only to use them directly in assays. Biomonitor iLite® cell-based products are covered by patents which are the property of Euro Diagnostica AB and any attempt to reproduce the delivered iLite® Assay Ready Cells is an infringement of these patents.

Subscribe to our mailing list

* indicates required